What’s New with PD-L1 as a Companion Diagnostic?

When:  Mar 24, 2021

Allie Cummings, B.S., HT(ASCP), Agilent Technologies

Predictive biomarker testing to inform treatment decision-making has radically influenced the practice of both pathology and oncology today. As the treatment scenario evolves, choosing the appropriate biomarker to select the right patients become vital. In this talk we will review the most up-to-date FDA approvals for checkpoint inhibitors and PD-L1 companion diagnostic assays. We will then compare the different PD-L1 scoring systems (TPS, CPS, IC, TC) and point out the role of clinical validation of PD-L1 assays. Finally, we will look at the future of cancer targeted therapies and emerging biomarkers.

Registration Dates

Early Registration Ends Wednesday, February 24, 2021